Is Zentalis Pharmaceuticals Llc (ZNTL) overvalued? · $257.7M cap
Zentalis Pharmaceuticals Llc (ZNTL) is a biotechnology company listed on NASDAQ.
This page asks whether Zentalis Pharmaceuticals Llc (ZNTL) looks expensive on cached numbers — not a short thesis.
Latest reported ZNTL revenue for 2025-09-30 was $0. Net income was -$26.7M. ZNTL currently screens at market cap $257.7M.
ZNTL currently screens at market cap $257.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ZNTL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ZNTL stock page for the full model, not this heading.
Not investment advice.